Geplant · 2019 bis 2027
Prostate cancer is the most frequent cancer in Western countries and castrate- resistant prostate cancer (CRPC) is its lethal form. Survival for CRPC patients with metastases now encompasses 30 months, while that for patients without metastases is about 5 years.
The primary objective is to evaluate the benefit of acetyl-salicylic acid and atorvastatin on overall survival (OS) (main endpoint)
We hypothesize that acetylsalicylic acid and atorvastatin im-prove survival and that this favorable effect occurs early, thus compatible with the survival of patients with CRPC.
This trial will test these two drugs as “add on” (patients and investigators will be free to use all approved and experimental drugs for CRPC).